Journal of Thoracic Oncology最新文献

{"title":"Tobacco News Update—From the IASLC Tobacco Control Committee","authors":"","doi":"10.1016/j.jtho.2024.05.008","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.05.008","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations for Post-Operative RadioTherapy After Complete Resection of Thymoma—a French DELPHI Consensus Initiative","authors":"Clémence Basse MD ,&nbsp;Jonathan Khalifa MD ,&nbsp;François Thillays MD ,&nbsp;Cécile Le Pechoux MD ,&nbsp;Jean-Michel Maury MD, PhD ,&nbsp;Pierre-Emmanuel Bonte PhD ,&nbsp;Alexandre Coutte MD ,&nbsp;Nicolas Pourel MD ,&nbsp;Vincent Bourbonne MD ,&nbsp;Olivier Pradier MD ,&nbsp;Aurélie Belliere MD ,&nbsp;Florence Le Tinier MD ,&nbsp;Mélanie Deberne MD ,&nbsp;Ronan Tanguy MD ,&nbsp;Fabrice Denis MD ,&nbsp;Laetitia Padovani MD ,&nbsp;Audrey Zaccariotto MD ,&nbsp;Thierry Molina MD, PhD ,&nbsp;Lara Chalabreysse MD, PhD ,&nbsp;Geoffrey Brioude MD, PhD ,&nbsp;Angela Botticella MD","doi":"10.1016/j.jtho.2024.04.003","DOIUrl":"10.1016/j.jtho.2024.04.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Thymomas are rare intrathoracic malignancies that can relapse after surgery. Whether or not Post-Operative RadioTherapy (PORT) should be delivered after surgery remains a major issue. RADIORYTHMIC is an ongoing, multicenter, randomized phase 3 trial addressing this question in patients with completely R0 resected Masaoka-Koga stage IIb/III thymoma. Experts in the field met to develop recommendations for PORT.</p></div><div><h3>Methods</h3><p>A scientific committee from the RYTHMIC network identified key issues regarding the modalities of PORT in completely resected thymoma. A DELPHI method was used to question 24 national experts, with 115 questions regarding the following: (1) imaging techniques, (2) clinical target volume (CTV) and margins, (3) dose constraints to organs at risk, (4) dose and fractionation, and (5) follow-up and records. Consensus was defined when opinions reached more than or equal to 80% agreement.</p></div><div><h3>Results</h3><p>We established the following recommendations: preoperative contrast-enhanced computed tomography (CT) scan is recommended (94% agreement); optimization of radiation delivery includes either a four-dimensional CT-based planning (82% agreement), a breath-holding inspiration breath-hold–based planning, or daily control CT imaging (81% agreement); imaging fusion based on cardiovascular structures of preoperative and planning CT scan is recommended (82% agreement); right coronary and left anterior descending coronary arteries should be delineated as cardiac substructures (88% agreement); rotational RCMI/volumetric modulated arc therapy is recommended (88% agreement); total dose is 50 Gy (81% agreement) with 1.8 to 2 Gy per fraction (94% agreement); cardiac evaluation and follow-up for patients with history of cardiovascular disease are recommended (88% agreement) with electrocardiogram and evaluation of left ventricular ejection fraction at 5 years and 10 years.</p></div><div><h3>Conclusion</h3><p>This is the first consensus for PORT in thymoma. Implementation will help to harmonize practices.</p></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.110 The Relationship Between Social Determinants of Health and Treatment Patterns and Outcomes in Patients with metastatic Non-Small Cell Lung Cancer","authors":"U. Tapan, Amanda Crosbie, Rick Szymialis, A. Botros, Ying Zhang, Nathan Hill","doi":"10.1016/j.jtho.2024.05.337","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.05.337","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial","authors":"Ying Cheng MD ,&nbsp;Yun Fan MD ,&nbsp;Yanqiu Zhao MD ,&nbsp;Dingzhi Huang MD ,&nbsp;Xingya Li MD ,&nbsp;Peng Zhang MD ,&nbsp;Mafei Kang MD ,&nbsp;Nong Yang MD ,&nbsp;Diansheng Zhong MD ,&nbsp;Zhen Wang MD ,&nbsp;Yan Yu MD ,&nbsp;Yu Zhang MD ,&nbsp;Jun Zhao MD ,&nbsp;Tai Qin MD ,&nbsp;Chenqi Chen MS ,&nbsp;Shiangjiin Leaw MD ,&nbsp;Wenjuan Zheng MD ,&nbsp;Yong Song MD ,&nbsp;RATIONALE-312 Study Group","doi":"10.1016/j.jtho.2024.03.008","DOIUrl":"10.1016/j.jtho.2024.03.008","url":null,"abstract":"<div><h3>Introduction</h3><p>Extensive-stage SCLC (ES-SCLC) prognosis remains poor. The phase 3 RATIONALE-312 study aimed to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for ES-SCLC.</p></div><div><h3>Methods</h3><p>RATIONALE-312 is a randomized, double-blind, placebo-controlled trial, conducted in the People's Republic of China. Eligible patients with previously untreated ES-SCLC were randomized 1:1 to receive four cycles of tislelizumab 200 mg or placebo, with etoposide plus carboplatin or cisplatin intravenously every 3 weeks, followed by tislelizumab 200 mg or placebo as maintenance. The primary end point was overall survival (OS). Secondary end points included progression-free survival and safety.</p></div><div><h3>Results</h3><p>Between July 22, 2019 and April 21, 2021, 457 patients were randomized to tislelizumab (n = 227) or placebo (n = 230), plus chemotherapy. Baseline demographics were generally balanced between arms. At the data cutoff (April 19, 2023), the median study follow-up was 14.2 months (interquartile range: 8.6–25.3). Tislelizumab plus chemotherapy exhibited a statistically significant OS benefit versus placebo plus chemotherapy (stratified hazard ratio = 0.75 [95% confidence interval (CI): 0.61–0.93]; one-sided <em>p</em> = 0.0040; median: 15.5 [95% CI: 13.5–17.1] versus 13.5 mo [95% CI: 12.1–14.9], respectively). Progression-free survival was significantly improved in the tislelizumab versus placebo arm (stratified hazard ratio = 0.64 [95% CI: 0.52–0.78]; <em>p</em> &lt; 0.0001; median: 4.7 [95% CI: 4.3–5.5] versus 4.3 mo [95% CI: 4.2–4.4], respectively). Grade greater than or equal to 3 treatment-related adverse events were reported in 86% of patients in each treatment arm and were mostly hematologic.</p></div><div><h3>Conclusions</h3><p>Tislelizumab plus chemotherapy exhibited statistically significant clinical benefit and manageable safety compared with placebo plus chemotherapy as first-line treatment in patients with advanced ES-SCLC.</p></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1556086424001151/pdfft?md5=b31c77f12e1d6962568f15faab6d5da6&pid=1-s2.0-S1556086424001151-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140068404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer","authors":"Frank C. Detterbeck MD ,&nbsp;Marcin Ostrowski MD ,&nbsp;Hans Hoffmann MD ,&nbsp;Ramón Rami-Porta MD, FETCS ,&nbsp;Ray U. Osarogiagbon M.B.B.S. ,&nbsp;Jessica Donnington MD, MSCR ,&nbsp;Maurizio Infante MD ,&nbsp;Mirella Marino MD ,&nbsp;Edith M. Marom MD ,&nbsp;Jun Nakajima MD ,&nbsp;Andrew G. Nicholson DM, FRCPath. ,&nbsp;Paul van Schil MD ,&nbsp;William D. Travis MD ,&nbsp;Ming S. Tsao MD ,&nbsp;John G. Edwards PhD, FRCS(C/Th) ,&nbsp;Hisao Asamura MD ,&nbsp;Members of the Staging and Prognostic Factors Committee and Advisory Boards","doi":"10.1016/j.jtho.2024.03.021","DOIUrl":"10.1016/j.jtho.2024.03.021","url":null,"abstract":"<div><h3>Introduction</h3><p>The goal of surgical resection is to completely remove a cancer; it is useful to have a system to describe how well this was accomplished. This is captured by the residual tumor (R) classification, which is separate from the TNM classification that describes the anatomic extent of a cancer independent of treatment. The traditional R-classification designates as R0 a complete resection, as R1 a macroscopically complete resection but with microscopic tumor at the surgical margin, and as R2 a resection that leaves gross tumor behind. For lung cancer, an additional category encompasses situations in which the presence of residual tumor is uncertain.</p></div><div><h3>Methods</h3><p>This paper represents a comprehensive review of evidence regarding these R categories and the descriptors thereof, focusing on studies published after the year 2000 and with adjustment for potential confounders.</p></div><div><h3>Results</h3><p>Consistent discrimination between complete, uncertain, and incomplete resection is revealed with respect to overall survival. Evidence regarding specific descriptors is generally somewhat limited and only partially consistent; nevertheless, the data suggest retaining all descriptors but with clarifications to address ambiguities.</p></div><div><h3>Conclusion</h3><p>On the basis of this review, the R-classification for the ninth edition of stage classification of lung cancer is proposed to retain the same overall framework and descriptors, with more precise definitions of descriptors. These refinements should facilitate application and further research.</p></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140571297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(24)00590-2","DOIUrl":"https://doi.org/10.1016/S1556-0864(24)00590-2","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.52 The Effect of Altered RNA Expression on Tumor Immune Infiltration in NSCLC: A Retrospective NGS Study","authors":"Tyler Faith ,&nbsp;Frank Weinberg ,&nbsp;Alicia Hulbert ,&nbsp;Lawrence Feldman ,&nbsp;Jen Godden ,&nbsp;Mary Pasquinelli ,&nbsp;Ryan Nguyen","doi":"10.1016/j.jtho.2024.05.288","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.05.288","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141593174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.54 A Multicenter, Open-Label Phase 1 Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Advanced Solid Tumors","authors":"Jun Zhang ,&nbsp;Jorge Chavez ,&nbsp;Nancy Chan","doi":"10.1016/j.jtho.2024.05.290","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.05.290","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141593231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.58 Real-world Outcomes in Patients With EGFR Wildtype Non-squamous Locally Advanced/Metastatic NSCLC Receiving Second- or Third-Line Docetaxel: Pooled Analysis From LUMINATE-101","authors":"Nicolas Girard ,&nbsp;Qingqing Xu ,&nbsp;D. Ross Camidge ,&nbsp;Shobhit Baijal ,&nbsp;Sudeep Karve ,&nbsp;Sophia Ng ,&nbsp;Rajesh Kamalakar ,&nbsp;Christine Ratajczak ,&nbsp;Allison Allen ,&nbsp;Shun Lu","doi":"10.1016/j.jtho.2024.05.293","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.05.293","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.84 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis","authors":"Tae Min Kim ,&nbsp;Valentina Guarneri ,&nbsp;Pei Jye Voon ,&nbsp;Boon Khaw Lim ,&nbsp;Jin-ji Yang ,&nbsp;Marie Wislez ,&nbsp;Cheng Huang ,&nbsp;Chong Kin Liam ,&nbsp;Julien Mazieres ,&nbsp;ye Mun Tho ,&nbsp;Hidetoshi Hayashi ,&nbsp;Nhung Nguyen ,&nbsp;Puey Ling Chia ,&nbsp;Filippo de Marinis ,&nbsp;Jo Raskin ,&nbsp;Qinghua Zhou ,&nbsp;Giovanna Finocchiaro ,&nbsp;Xiuning Le ,&nbsp;Daniel Tan ,&nbsp;Richard M. O’Hara Jr. ,&nbsp;Yi-Long Wu","doi":"10.1016/j.jtho.2024.05.315","DOIUrl":"https://doi.org/10.1016/j.jtho.2024.05.315","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}